RTP Mobile Logo
Select Publications

Bond DA et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv 2021;[Online ahead of print]. Abstract

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphomab (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract

Cohen JB, Kahl BS. Initial treatment of early stage and low tumor burden follicular lymphoma. Hematol Oncol Clin North Am 2020;34(4):663-72. Abstract

Ghobadi A et al. Blinatumomab consolidation post autologous hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma. ASH 2020;Abstract 1450.

Herrera AF et al. SWOG S1826: A phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma. ASH 2020;Abstract 2969.

Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract

Jacobson C et al. Primary analysis of Zuma-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2020;Abstract 700.

Kahl B. High-risk follicular lymphoma: Treatment options. Hematol Oncol 2021;39(Suppl

1):94-9. Abstract

Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-22. Abstract

Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract

Nowakowski GS et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup study ECOG-ACRIN E1412. J Clin Oncol 2021;39(12):1329-38. Abstract

Ramos CA et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2020;38(32):3794-804. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Smith MR et al. ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. ASCO 2021;Abstract 7503.

Sohail MA et al. Patterns and risk of CNS recurrence after R-EPOCH treatment for double/triple hit lymphoma. ASH 2020;Abstract 1218.

Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410-21. Abstract

Yasenchak CA et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. ASH 2020;Abstract 471.